Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Given Consensus Recommendation of “Buy” by Analysts

Shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) have earned a consensus recommendation of “Buy” from the eight ratings firms that are currently covering the stock, MarketBeat reports. Six equities research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. The average 1-year price target among analysts that have issued ratings on the stock in the last year is $32.83.

Several equities analysts recently commented on CPRX shares. Wall Street Zen upgraded Catalyst Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Friday, February 28th. Robert W. Baird increased their price objective on Catalyst Pharmaceuticals from $28.00 to $32.00 and gave the stock an “outperform” rating in a research note on Monday, March 3rd. Stephens restated an “overweight” rating and issued a $33.00 target price on shares of Catalyst Pharmaceuticals in a research note on Thursday, February 27th. Cantor Fitzgerald raised shares of Catalyst Pharmaceuticals to a “strong-buy” rating in a report on Thursday. Finally, HC Wainwright reissued a “buy” rating and set a $35.00 price target on shares of Catalyst Pharmaceuticals in a report on Friday, February 28th.

Insider Activity

In other Catalyst Pharmaceuticals news, insider Gary Ingenito sold 200,000 shares of the stock in a transaction dated Tuesday, May 13th. The shares were sold at an average price of $23.68, for a total transaction of $4,736,000.00. Following the sale, the insider now owns 68,873 shares of the company’s stock, valued at $1,630,912.64. This represents a 74.38% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 10.40% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Catalyst Pharmaceuticals

A number of large investors have recently modified their holdings of the stock. Cim Investment Management Inc. acquired a new stake in shares of Catalyst Pharmaceuticals in the first quarter valued at approximately $208,000. Strs Ohio acquired a new stake in shares of Catalyst Pharmaceuticals in the 1st quarter valued at $994,000. Intech Investment Management LLC increased its stake in shares of Catalyst Pharmaceuticals by 6.5% in the 1st quarter. Intech Investment Management LLC now owns 70,087 shares of the biopharmaceutical company’s stock valued at $1,700,000 after buying an additional 4,261 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its position in shares of Catalyst Pharmaceuticals by 99.4% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 526,297 shares of the biopharmaceutical company’s stock worth $12,763,000 after acquiring an additional 262,392 shares during the last quarter. Finally, Fred Alger Management LLC acquired a new position in shares of Catalyst Pharmaceuticals during the first quarter valued at $1,246,000. 79.22% of the stock is currently owned by institutional investors and hedge funds.

Catalyst Pharmaceuticals Stock Up 2.0%

Shares of CPRX opened at $25.87 on Friday. The company has a 50-day moving average price of $23.64 and a two-hundred day moving average price of $22.74. The stock has a market cap of $3.16 billion, a price-to-earnings ratio of 21.92, a P/E/G ratio of 3.31 and a beta of 0.70. Catalyst Pharmaceuticals has a 12 month low of $14.75 and a 12 month high of $26.16.

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.